Cepeginterferon alfa-2B
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Cepeginterferon alfa-2B
- Accession Number
- DB12814
- Description
Cepeginterferon alfa-2B is under investigation in clinical trial NCT01889433 (An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Interferons - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Algeron
- Cepeginterferon Alfa 2 B
- Pegylated human interferon A-2B
- External IDs
- Cepeginterferon alfa-2B
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Cepeginterferon alfa-2B. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Cepeginterferon alfa-2B. Acenocoumarol The metabolism of Cepeginterferon alfa-2B can be decreased when combined with Acenocoumarol. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Cepeginterferon alfa-2B. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cepeginterferon alfa-2B. Acyclovir The metabolism of Acyclovir can be decreased when combined with Cepeginterferon alfa-2B. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Cepeginterferon alfa-2B. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cepeginterferon alfa-2B. Agomelatine The metabolism of Agomelatine can be decreased when combined with Cepeginterferon alfa-2B. Albendazole The metabolism of Albendazole can be decreased when combined with Cepeginterferon alfa-2B. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Categories
- ATC Codes
- L03AB14 — Cepeginterferon alfa-2b
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 6J022WTC4Y
- CAS number
- 1192706-52-7
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911385
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Hepatitis / Hepatitis C Viral Infection 1 3 Completed Treatment Hepatitis / Hepatitis C Viral Infection / Hepatitis C/ Human Immunodeficiency Virus Coinfection 1 2 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 2, 3 Completed Treatment Hepatitis / Hepatitis C Viral Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Delaporte E, Renton KW: Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcriptional and post-transcriptional levels by conditions resulting in interferon-alpha/beta induction. Life Sci. 1997;60(10):787-96. doi: 10.1016/s0024-3205(97)00006-4. [PubMed:9064483]
Drug created on October 20, 2016 18:27 / Updated on June 12, 2020 10:53
Are you a data scientist
working on drug development?
DrugBank has a breadth of high quality data, organized and structured to support drug development research.